$IRTC

Murphy Patrick Michael sold $884K of IRTC

Murphy Patrick Michael (CBO and CLO) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.

Original reporting
SEC EDGAR · Murphy Patrick Michael
Published Aug 11, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may monitor insider activity, but this disclosure alone does not provide new operational or financial information.

03

What to watch

Insider sales are often planned for liquidity or diversification; the article lacks context on total holdings, prior sales cadence, or any concurrent company-specific catalyst.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, covering a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC disclosed an officer sale of 7,093 shares on 2026-08-10 for about $884,156, per an SEC Form 4 filing.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing provides transaction size, price, and role (CBO and CLO) but no accompanying company guidance, operational update, or enforcement/regulatory action.

Market effects

No clear sector read-through from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Murphy Patrick Michael

    Officer (CBO and CLO) who sold 7,093 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

$IRTCMed

Why iRhythm (IRTC) Shares Are Trading Lower Today

iRhythm Technologies (IRTC) shares fell about 2.8% after Truist cut its price target to $18 from $160, keeping a Buy rating. The move followed iRhythm’s strong Q2 results, including $224.2M revenue (+20.1% YoY) and EPS of $0.58, and a raised FY revenue guidance midpoint to $885M.

$IRTCHighAI 9/10

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

iRhythm Holdings (IRTC) reported Q2 2026 adjusted EPS of 58 cents versus an adjusted loss of 32 cents a year earlier, beating the Zacks Consensus Estimate by 5900%. Revenue rose 20.1% to $224.2 million. Gross margin increased to 72.8%. Full-year 2026 revenue guidance was raised to $880 million-$890 million and adjusted EBITDA margin to 13%-14%.

$IRTCMedAI 8/10

IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter

iRhythm Technologies (IRTC) reported Q2 revenue of $224.2M, above analysts’ $219.2M estimate, and adjusted EPS of $0.58. Adjusted EBITDA was $43.3M versus $26.13M estimates. The company slightly raised full-year revenue guidance to $885M. It also agreed to acquire VitalConnect to expand cardiac monitoring offerings and expects margin gains from automation.